Member Posts > Cardiol Therapeutics Leads the Next Era of Cardiovascular Innovation with CRD-38
Cardiol Therapeutics Inc. (NASDAQ: CRDL, TSX: CRDL) is at the forefront of revolutionizing heart failure treatment, as validated by a groundbreaking study published in JACC: Basic to Translational Science. CRD-38, a first-in-class subcutaneous cannabidiol (CBD) formulation, has demonstrated the ability to prevent heart failure progression by preserving mitochondrial function and reducing fibrosis and inflammation-key factors that drive the condition.
Why CRD-38 is a Game-Changer
🚀 Targets the Root Cause - Unlike traditional HFpEF treatments that focus on symptom management, CRD-38 directly addresses inflammation and cardiac fibrosis, stopping heart failure at its source.
🚀 First-of-Its-Kind Therapy - No current FDA-approved therapies use cannabidiol to treat heart failure. CRD-38 could be the first cannabinoid-based cardiovascular drug to enter the market.
🚀 Designed for the Future - With a subcutaneous administration route, CRD-38 is optimized for long-term patient adherence and improved bioavailability, setting a new standard for cardiovascular treatments.
What's Next?
With IND-enabling studies nearing completion, Cardiol is gearing up for clinical trials and regulatory approvals, taking one step closer to changing the future of heart failure treatment forever.

#FutureOfMedicine #CRD38 #CardiolTherapeutics #HeartHealth #MedicalInnovation #CannabinoidTherapy #NextGenBiotech